Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Shuji Ogino, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Shuji Ogino and Massimo Loda.
Connection Strength

2.203
  1. MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res. 2016 Jan; 4(1):33-40.
    View in: PubMed
    Score: 0.163
  2. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103(7):1025-33.
    View in: PubMed
    Score: 0.114
  3. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26(35):5713-20.
    View in: PubMed
    Score: 0.101
  4. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58(1):90-6.
    View in: PubMed
    Score: 0.100
  5. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2008 Feb; 21(2):150-8.
    View in: PubMed
    Score: 0.095
  6. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007 Jul; 9(3):305-14.
    View in: PubMed
    Score: 0.092
  7. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
    View in: PubMed
    Score: 0.090
  8. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007 Jun; 38(6):842-9.
    View in: PubMed
    Score: 0.090
  9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007 Apr; 38(4):614-20.
    View in: PubMed
    Score: 0.089
  10. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol. 2007 Apr; 38(4):585-92.
    View in: PubMed
    Score: 0.089
  11. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol. 2007 Jan; 20(1):15-22.
    View in: PubMed
    Score: 0.088
  12. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006 Nov; 8(5):582-8.
    View in: PubMed
    Score: 0.088
  13. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006 Oct; 210(2):147-54.
    View in: PubMed
    Score: 0.087
  14. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006 Sep; 30(9):1175-83.
    View in: PubMed
    Score: 0.087
  15. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006 Sep 01; 66(17):8625-32.
    View in: PubMed
    Score: 0.087
  16. USP2a is an oncogenic isopeptidase and a potential target in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14522.
    View in: PubMed
    Score: 0.086
  17. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia. 2006 Jun; 8(6):458-64.
    View in: PubMed
    Score: 0.085
  18. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol. 2006 Aug; 19(8):1083-90.
    View in: PubMed
    Score: 0.085
  19. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006 May; 8(2):209-17.
    View in: PubMed
    Score: 0.085
  20. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006 Jul; 55(7):1000-6.
    View in: PubMed
    Score: 0.083
  21. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006 Jan; 19(1):59-68.
    View in: PubMed
    Score: 0.083
  22. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
    View in: PubMed
    Score: 0.081
  23. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005 Aug; 7(3):413-21.
    View in: PubMed
    Score: 0.081
  24. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
    View in: PubMed
    Score: 0.027
  25. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
    View in: PubMed
    Score: 0.025
  26. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007 Sep; 9(4):441-51.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.